Nuo Therapeutics (AURX) CEO/CFO Jorden Emerson Buys 8,773 Shares

What Happened

• Jorden David Emerson, CEO, CFO and a director of Nuo Therapeutics (AURX), reported two open‑market purchases on an amended Form 4. He acquired 789 shares on 2026-08-27 at $1.07 reported ($844) and 7,984 shares on 2026-08-28 at a reported weighted average price of $1.09 ($8,695), for a total of 8,773 shares costing about $9,539. Purchases are typically viewed as a more bullish signal than sales because the insider is adding to their stake.

Key Details

• Transaction dates and prices:
  • 2026-08-27: Purchase of 789 shares at $1.07 (reported value $844).
  • 2026-08-28: Purchase of 7,984 shares at a reported weighted average price $1.09 (reported value $8,695).
• Aggregate: 8,773 shares purchased for approximately $9,539.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The Aug 28 price is a weighted average; those shares were purchased in multiple trades at prices ranging $1.08–$1.10. The reporting person will provide transaction‑by‑transaction details on request to the issuer, shareholders, or SEC staff.
• Filing status: This is an amended Form 4 filed 2026-08-31 reporting trades on 2026-08-27 and 2026-08-28. Form 4s are normally due within two business days of the transaction; because this filing is an amendment, investors may want to check whether an earlier timely filing was corrected.

Context

• These were straightforward open‑market purchases (transaction code P). There’s no indication of option exercises, awards, gifts, or tax withholding in this filing. As always, purchases by executives can be informative but do not guarantee future company performance.